Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | IL1B | P01584 | 2/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL262567 | 1.00 | NPC1 (0.42) | NPC1RAB9AIL1BNPY5RHCRTR1 | |
| SCHEMBL3390142 | 1.00 | NPC1 (0.42) | NPC1RAB9AIL1BNPY5RHCRTR1 | |
| SCHEMBL262568 | 1.00 | NPC1 (0.42) | NPC1RAB9AIL1BNPY5RHCRTR1 | |
| SCHEMBL3389647 | 0.83 | IL1B (0.35) | IL1BHCRTR1HCRTR2 | |
| SCHEMBL3389643 | 0.83 | IL1B (0.35) | IL1BHCRTR1HCRTR2 | |
| SCHEMBL262092 | 0.81 | HCRTR1 (0.36) | IL1BHCRTR1HCRTR2 | |
| SCHEMBL262093 | 0.81 | HCRTR1 (0.36) | IL1BHCRTR1HCRTR2 | |
| SCHEMBL6523847 | 0.79 | NPC1 (0.41) | NPC1RAB9AIL1BHCRTR1HCRTR2 | |
| SCHEMBL3387279 | 0.79 | IL1B (0.44) | IL1BHCRTR1HCRTR2 | |
| SCHEMBL3387277 | 0.79 | IL1B (0.44) | IL1BHCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144760-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-06-10 | — | — | US | disclosed |
| WO-2010063663-A1 | N-{[(IR,4S,6R-3-(2-PYRIDINYLCARBONYL)-3-AZABICYCLO [4.1.0]HEPT-4-YL] METHYL}-2-HETEROARYLAMINE DERIVATIVES AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2010-06-10 | — | — | WO | disclosed |
| US-20100144760-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144760-A1 | NOVEL COMPOUNDS | HTR3B, HTR1B, HTR2B | NPC1 139/4885RAB9A 308/4885IL1B 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.